Trial Profile
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Obinutuzumab (Primary) ; Chlorambucil
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms Elevate CLL TN; ELEVATE-TN
- Sponsors Acerta Pharma
- 12 Dec 2023 Updated results at 74.5 month of follow-up assessing efficacy of acalabrutinib-obinutuzumab in treatment-naive chronic lymphocytic leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing the impact of targeted agents in fully mitigating the detrimental effects of CLL on overall survival by comparing the 5-year OS of treatment-naive CLL pts in phase 3 clinical trials with the 5-year OS of age- and gender-matched general population (AGMGP) in Italy and the US (RESONATE2, ILLUMINATE, ALLIANCE, ELEVATE-TN, CLL14, GLOW, ECOG1912, FLAIR, and CLL13) were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 12 Dec 2023 Results of post hoc analysis, assessing the impact on survival outcomes of acala discontinuation and dose modifications occurring in the first year of treatment , presented at the 65th American Society of Hematology Annual Meeting and Exposition